Boehringer Ingelheim’s Pagnotta Talks Adalimumab And Interchangeability
As Cyltezo Rival To Humira Hits US, Firm Says It Is ‘Uniquely Positioned’ In Biosimilars Market
Executive Summary
As Boehringer Ingelheim launches the first – and so far, only – interchangeable US adalimumab biosimilar, the firm’s biosimilar commercial brand lead Stephen Pagnotta talks to Generics Bulletin about how the interchangeability designation puts the firm in a unique position when it comes to competing with Humira.